Evidence map›Paper›PMID 39989508›Full record

ReviewTherapeutic advances in rare disease

Patient leadership and partnerships accelerate therapies for SCN8A and other developmental and epileptic encephalopathies.

Gabrielle Conecker, JayEtta Hecker, Michael F Hammer

Abstract readReview
In one paragraph

Review in Therapeutic advances in rare disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Gabrielle ConeckerInternational SCN8A Alliance, 1234 Crittenden St NW, Washington, D.C. 20011, USA.ORCID https://orcid.org/0000-0003-3274-0292
JayEtta HeckerInternational SCN8A Alliance, Washington, D.C., USA.ORCID https://orcid.org/0009-0001-2704-5044
Michael F HammerInternational SCN8A Alliance, University of Arizona BIO5 Institute, Tucson, AZ, USA.ORCID https://orcid.org/0000-0003-0172-429X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Families are a driving force in accelerating the understanding and science of SCN8A. The urgency felt by families facing the absence of treatments for their children makes them uniquely positioned to advance therapies through advocacy, data sharing, and partnerships. The International SCN8A Alliance (Alliance) brings families together to collaborate on advancing the science of SCN8A. The Alliance hosts SCN8A

Indexed as

collaborationDevelopmental and Epileptic Encephalopathydiagnostic odysseygenetic epilepsiesmodified Delphipatient registry

Identifiers

PMID39989508
PMCPMC11843689

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.